The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials

阿利罗库单抗 Evolocumab公司 医学 PCSK9 内科学 随机对照试验 优势比 糖尿病 安慰剂 狼牙棒 血脂谱 他汀类 胃肠病学 内分泌学 胆固醇 载脂蛋白B 脂蛋白 心肌梗塞 载脂蛋白A1 低密度脂蛋白受体 替代医学 病理 传统PCI
作者
Egidio Imbalzano,Federica Ilardi,Luana Orlando,Basilio Pintaudi,Gianluigi Savarese,Giuseppe Rosano
出处
期刊:European Heart Journal - Cardiovascular Pharmacotherapy [Oxford University Press]
卷期号:9 (4): 318-327 被引量:10
标识
DOI:10.1093/ehjcvp/pvad019
摘要

ABSTRACT Objective To evaluate the specific effects of PCSK9 inhibitors (i.e. alirocumab and evolocumab) on major cardiovascular events (MACE) and lipid profile in patients with diabetes. Methods and results We conducted a systematic review of literature according to the PRISMA statement. A total of eight randomized control trials (RCTs) enrolling 20 651 patients with diabetes were included. The mean follow-up was 51 weeks. We included RCTs that had compared the subtilisin–kexin type 9 inhibitors (PCSK9i) alirocumab and evolocumab with placebo in subjects with hypercholesterolaemia and diabetes mellitus. MACE occurred in 8.7% of patients with diabetes randomized to PCSK9i vs. 11.0% of those randomized to placebo. Thus, the use of alirocumab or evolocumab reduced MACE by 18% [odds ratio (OR): 0.82; 95% confidence interval (CI): 0.74–0.90]. Compared with control group, the use of PCSK9 inhibitors was associated with a significant percentage change from baseline in low-density lipoprotein cholesterol [mean difference (MD) –58.48%; 95% CI: –63.73 to –53.22%, P < 0.0001], high-density lipoprotein cholesterol (HDL-C) (MD 5.21%; 95% CI: 3.26–7.17%), triglycerides (MD –14.59%; 95% CI: –19.42 to –9.76%), non-HDL-C (MD –48.84%; 95% CI: –54.54 to –43.14%), and total cholesterol (MD –33.76%; 95% CI: –38.71 to –28.8%). Moreover, a significant reduction of lipoprotein(a) (MD –32.90%; 95% CI: –38.55 to –27.24%) and apolipoprotein B (MD –46.83%; 95% CI: –52.71 to ––40.94%) were observed in PCSK9i group compared with placebo. Conclusion PCSK9i appear to be effective in reducing the risk of MACE and in improving lipid profiles of subjects with diabetes and dyslipidaemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Lontano完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
从容的巧曼完成签到,获得积分10
2秒前
2秒前
练习时长两年半应助夏林采纳,获得10
3秒前
善学以致用应助Z可采纳,获得10
3秒前
3秒前
小学生发布了新的文献求助10
3秒前
舒适的天奇完成签到 ,获得积分10
3秒前
4秒前
海棠依旧完成签到,获得积分10
4秒前
4秒前
费凝海完成签到,获得积分10
4秒前
霸气纹完成签到,获得积分10
4秒前
paradox发布了新的文献求助10
5秒前
糕糕发布了新的文献求助10
5秒前
疯狂的莫言完成签到,获得积分10
6秒前
6秒前
7秒前
naomi发布了新的文献求助30
7秒前
8秒前
8秒前
8秒前
8秒前
8秒前
BOYA完成签到,获得积分10
8秒前
melon完成签到,获得积分10
10秒前
艺术家完成签到,获得积分10
10秒前
10秒前
10秒前
酷酷的小张完成签到,获得积分10
10秒前
11秒前
尊敬的小刺猬完成签到,获得积分10
11秒前
11秒前
jessica发布了新的文献求助10
12秒前
情怀应助memedaaaah采纳,获得10
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974943
求助须知:如何正确求助?哪些是违规求助? 3519467
关于积分的说明 11198482
捐赠科研通 3255728
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877261
科研通“疑难数据库(出版商)”最低求助积分说明 806224